Thursday, September 15, 2022
Neurovation Labs, Inc., a biotechnology company focused on diagnosing and treating Post-traumatic Stress Disorder (PTSD) through physiological biomarkers, has announced the issuance of U.S. Patent No. 11,439,715 by the U.S. Patent and Trademark Office on September 13, 2022. The patent, titled "Compositions and Methods to Detect GluA1 in Brain and to Identify the Presence of GluA1-Mediated Post-Traumatic Stress Disorder and Other Neurological Disorders," encompasses novel radiotracer compositions and methods for detecting GluA1 and GluA1-containing receptors in the central nervous system.
Dr. Jennifer Perusini, Co-Founder and Chief Executive Officer of Neurovation Labs, explained the significance of the patent: "The compounds protected by this patent are part of a series of radiotracers that Neurovation Labs is developing to enable objective diagnosis of brain disorders and gain deeper insights into the mechanisms underlying PTSD and other brain traumas. These compounds, along with the methods covered by the patent, offer a novel and targeted approach to mental healthcare, allowing us to definitively detect central nervous system disorders. Our goal is to visualize, measure, and ultimately address previously invisible wounds in patients."
Neurovation Labs exclusively owns this patent, which is the second one to be issued from their extensive intellectual property portfolio resulting from their research and development efforts. The company is currently exploring potential applications and extensions of its technology to traumatic brain injury (TBI) and micro-TBI, with the support of a U.S. Air Force Small Business Innovation Research (SBIR) contract.
